Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASSAVA SCIENCES, INC.

(SAVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Cassava Sciences, Inc.
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The CompanyÔÇÖs products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The CompanyÔÇÖs scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.

Number of employees : 11 people.
Managers
Name Title Age Since
Remi Barbier Chairman, President & Chief Executive Officer 61 1998
Eric J. Schoen Chief Financial Officer 52 2018
Nadav Friedmann Director, Chief Operating & Medical Officer 78 2004
James W. Kupiec, Dr. Chief Clinical Development Officer - 2021
Michael Zamloot Senior Vice President-Technical Operations - -
George B. Thornton, Dr. Senior Vice President-Technology - -
Robert Z. Gussin, Dr. Independent Director 83 2003
Sanford R. Robertson Independent Director 89 1998
Michael J. O'Donnell Secretary & Independent Director 62 2011
Patrick J. Scannon, Dr. Independent Director 73 2007
Members of the board
Name Title Age Since
Remi Barbier Chairman, President & Chief Executive Officer 61 1998
Nadav Friedmann Director, Chief Operating & Medical Officer 78 2004
Robert Z. Gussin, Dr. Independent Director 83 2003
Sanford R. Robertson Independent Director 89 1998
Michael J. O'Donnell Secretary & Independent Director 62 2011
Patrick J. Scannon, Dr. Independent Director 73 2007
Richard Jon Barry Independent Director 62 2021
Shareholders
NameEquities%
Armistice Capital LLC 2,164,000 5.41%
The Vanguard Group, Inc. 1,864,160 4.66%
First Eagle Investment Management LLC 1,695,395 4.24%
Remi Barbier 1,083,721 2.71%
SSgA Funds Management, Inc. 939,086 2.35%
BlackRock Fund Advisors 938,234 2.34%
Sanford R. Robertson 920,095 2.30%
CaaS Capital Management LP 687,260 1.72%
Nantahala Capital Management LLC 647,053 1.62%
Geode Capital Management LLC 638,473 1.60%
Company contact information
Cassava Sciences, Inc.
7801 North Capital of Texas Highway
Suite 260
Austin, TX 78731

Phone : +1.512.501.2444
Fax : +1.512.614.0414
Web : http://www.cassavasciences.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Cassava Sciences, Inc.
Sector Bio Therapeutic Drugs
Connections : Cassava Sciences, Inc.